Abstract:Cardiac surgery is associated with hyperglycemia, which in turn is associated with adverse post-surgical outcomes such as wound infections, acute renal failure, and mortality. This pilot study seeks to determine if Dexcom G6Pro continuous glucose monitor (Dexcom G6Pro CGM) is accurate during the postoperative cardiac surgery period when fluid shifts, systemic inflammatory response syndrome (SIRS), and vasoactive medications are frequently encountered, compared to standard glucose monitoring techniques. Methods This study received IRB approval. In this prospective study, correlation between clinical and Dexcom glucose readings was evaluated. Clinical glucose (blood gas, metabolic panel, and point of care [POC]) dataset included 1428 readings from 29 patients, while the Dexcom G6Pro CGM data included 45,645 data points following placement to upper arm. Additionally, average clinical measurements of day and overnight temperatures and hemodynamics were evaluated. Clinical and Dexcom data were restricted to being at least 1 hour after prior clinical reading Matching Dexcom G6Pro CGM data were required within 5 minutes of clinical measure. Data included only if taken at least 2 hours after Dexcom G6Pro CGM insertion (warm-up time) and and analyzed only following ICU admission. Finally, a dataset excluding the first 24 hours after ICU admission was created to explore stability of the device. Patients remained on Dexcom G6Pro CGM until discharge or 10 days postoperatively. Results The population was 71% male, 14% with known diabetes; 66% required IV insulin infusion. The Clarke error grid plot of all measures post-ICU admission showed 53.5% in Zone A, 45.9% in Zone B, and 0.6% (n=5) in Zones D or E. The restricted dataset that excluded the first 24 hours post-ICU admission showed 55.9% in Zone A, 43.9% in Zone B, and 0.2% in Zone D. Mean absolute relative difference (MARD) between clinical and Dexcom G6Pro CGM measures was 20.6% and 21.6% in the entire post-ICU admission dataset, and the dataset excluding the first 24 hours after ICU admission, respectively. In the sub-analysis of the 12 patients who did not have more than a 5-minute tap in the operating room, a Consensus error grid, demonstrated that after ICU admission, percentage in zone A was 53.9%, zone B 45.4%, and zone C 0.7%. Similar percentages were obtained removing the first 24 hours post-ICU admission. These numbers are very similar to the entire cohort. A consensus error grid created post-ICU admission demonstrated: (Zone A) 54%, (Zone B) 45%, (Zone C) 0.9%, and the following for the dataset created excluding the first 24 hours: (Zone A) 56%, (Zone B) 44%, (Zone C) 0.4%, which demonstrated very close agreement with the original Clarke error grid. No adverse events were reported. Conclusions Almost 100% of Dexcom G6Pro CGM and clinical data matching points fell within areas considered as giving clinically correct decisions (Zone A) and clinically uncritical decisions (Zone B). However, the relatively high MARD precludes its use for both monitoring and treatment in the clinical context. As technology evolves, interstitial glucose monitoring may become an important tool to limit iatrogenic anemia and mitigate glycemic fluctuations.

Testing the Real-World Accuracy of the Dexcom G6 Pro CGM During the Insulin-Only Bionic Pancreas Pivotal Trial

Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes

Performance of a new real-time continuous glucose monitoring system: A multicenter pilot study.

Comparing the accuracy of transcutaneous sensor and 90-day implantable glucose sensor

FreeStyle Libre and Dexcom G4 Platinum sensors: Accuracy comparisons during two weeks of home use and use during experimentally induced glucose excursions

647-P: Improved Glycemic Control and Continuous Glucose Monitoring (CGM) Utilization: A Comparison of Real-Time CGM and Intermittent Scanning CGM

Continuous Glucose Monitoring Using the Dexcom G6 in Cardiac Surgery during the Postoperative Period.

Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real‐world analysis

Performance of a Novel Continuous Glucose Monitoring Device in People With Diabetes

Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems

Accuracy of a Continuous Glucose Monitor During Pediatric Type 1 Diabetes Inpatient Admissions

Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial

Hypoglycemic Accuracy and Improved Low Glucose Alerts of the Latest Dexcom G4 Platinum Continuous Glucose Monitoring System

The Dexcom Community Glucose Monitoring Project: 6-Month Results Using Continuous Glucose Monitoring in Type 2 Diabetes

REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes

Accuracy of a Real-Time Continuous Glucose Monitor in Pediatric Diabetic Ketoacidosis Admissions

Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes

980-P: Continuous Glucose Monitor Improves Glycemic Control in Youth-Onset Type 2 Diabetes

Measures of Accuracy for Continuous Glucose Monitoring and Blood Glucose Monitoring Devices

Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes

Accuracy of Two Continuous Glucose Monitoring Devices During Aerobic and High-Intensity Interval Training in Individuals with Type 1 Diabetes